Healthcare / BiotechnologyCanadian Sec
$0.10
-0.01 (-4.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.2M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
103.8%
↑Gross Margin
56.6%
↑Debt/Equity
-0.50
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.0%
FCF CAGR
—
FCF margin
-55.3%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.1M · net income $-5.4M · FCF $-1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.1M | $2.1M | $1.0M | $718298.00 | $1.8M |
| Net Income | $-5.4M | $-5.4M | $-4.3M | $-3.8M | $-8.5M |
| EBITDA | $-3.9M | $-3.9M | $-3.0M | $-2.9M | $-7.6M |
| EPS | -0.04 | -0.04 | -0.04 | -0.04 | -0.08 |
| Gross Margin | 56.6% | 56.6% | 55.2% | 51.8% | 76.8% |
| Operating Margin | -200.1% | -200.1% | -302.4% | -493.4% | -245.6% |
| Net Margin | -259.2% | -259.2% | -422.0% | -530.4% | -484.5% |
| Balance Sheet | |||||
| Debt/Equity | -0.50 | -0.50 | -0.71 | -0.60 | 4.67 |
| Current Ratio | 0.08 | 0.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.2M | $-1.2M | $-2.3M | $-863917.00 | $-3.0M |
| Returns | |||||
| ROE | 103.8% | 103.8% | 136.4% | 142.7% | -3373.9% |
| Valuation | |||||
| P/B | — | — | — | — | 117.52 |
| Growth & Yield | |||||
| Revenue Growth | 104.3% | 104.3% | 42.1% | -59.0% | — |
| EPS Growth | 0.0% | 0.0% | 0.0% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.04
Residual
-50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.